Five Prime Therapeutics

The top 10 biopharma M&A deals in 2021
Fierce Pharma
Tue, 01/18/22 - 10:53 am
M&A
CSL
Vifor
Jazz Pharmaeuticals
GW Pharma
Novo Nordisk
Dicerna
Horizon Therapeutics
Viela Bio
Perrigo
HRA Pharma
Sanofi
Kadmon
Merck
Acceleron
Pfizer
Arena Pharmaceuticals
Translate Bio
Trillium Therapeutics
Amgen
Five Prime Therapeutics
Quiet times return for biopharma takeouts
EP Vantage
Wed, 04/14/21 - 09:26 am
M&A
Alexion
Amgen
AstraZeneca
Biogen
Five Prime Therapeutics
Gilead Sciences
GW Pharma
Horizon Therapeutics
Immunomedics
Jazz Pharmaceutical
Kymab
Merck
Pandion
Sanofi
Viela Bio
How Five Prime suitor Amgen battled multiple companies for the biotech—and won
Fierce Biotech
Fri, 03/19/21 - 10:48 am
Amgen
M&A
Five Prime Therapeutics
SEC
oncology
Amgen adds gastric cancer drug candidate in $1.9 billion Five Prime Therapeutics deal
Reuters
Thu, 03/4/21 - 10:29 am
Amgen
Five Prime Therapeutics
M&A
gastric cancer
Why Five Prime Therapeutics Stock Gained 312% in November
Motley Fool
Tue, 12/8/20 - 10:46 am
Five Prime Therapeutics
stomach cancer
bemarituzumab
Five Prime looks to turn a corner
EP Vantage
Wed, 11/11/20 - 10:55 am
Five Prime Therapeutics
stomach cancer
bemarituzumab
Five Prime Therapeutics’ pancreatic cancer combo with Opdivo a bust
Fierce Biotech
Tue, 02/18/20 - 08:29 pm
Five Prime Therapeutics
cabiralizumab
Bristol-Myers Squibb
Opdivo
pancreatic cancer
Five Prime's new CEO wields ax, laying off 70 staffers
Fierce Biotech
Fri, 10/11/19 - 10:41 am
Five Prime Therapeutics
layoffs
After swinging the ax on staffers, Five Prime Therapeutics loses CEO
Fierce Biotech
Fri, 09/20/19 - 09:25 am
Five Prime Therapeutics
Aron Knickerbocker
June 3 ASCO Quick Takes: ORR of 32% for Celgene's iberdomide in MM; plus Five Prime, Iovance and more
BioCentury
Mon, 06/3/19 - 08:17 pm
ASCO 2019
Celgene
Multiple Myeloma
Five Prime Therapeutics
Iovance
Merck
Moderna Therapeutics
Eli Lilly
ICR
Five Prime Therapeutics Cuts 20% of Staff as Part of Restructuring
BioSpace
Wed, 01/16/19 - 10:08 am
Five Prime Therapeutics
layoffs
restructuring